

**CB SCIENTIFIC, INC.**

**CB Scientific, Inc. announces definitive purchase agreement to acquire  
commercial ambulatory ECG device manufacturer Datrix, LLC**

**November 4, 2020**

(Date of Report)

**CB SCIENTIFIC, INC.**

(Exact Name of Registrant as Specified in its Charter)

**340 State Place, Escondido, CA 92029**

(Address of principle executive offices)

**888-225-0870**

(Registrant's telephone number, including area code)

# CB Scientific, Inc. (CBSC)

## CB Scientific, Inc. announces definitive agreement to acquire commercial ambulatory ECG device manufacturer, Datrix, LLC

CB Scientific, Inc. (CBSC), in an ongoing effort to expand its products and services in the Remote Cardiac Ambulatory ECG market, both domestically and internationally, is pleased to announce a definitive purchase agreement to acquire Datrix, LLC, a global ambulatory device manufacturer based in Escondido, California. Datrix, LLC brings to CBSC a diversely experienced team of highly qualified individuals with extensive knowledge of design and engineering related to medical devices utilized in this ever-expanding market. This acquisition further strengthens our digital offering with the addition of an existing commercially available product line which includes wireless Mobile Cardiac Telemetry, Cardiac Event, Extended and Standard Holter monitoring through the Datrix Sirona and VX3 devices.

This acquisition will provide CBSC and its subsidiary My-Cardia (USA) Inc. the ability to enhance and improve our current proprietary My-Cam device and to expand into other cardiac arrhythmia testing offerings quickly. This also will open new avenues into the existing Remote Cardiac Ambulatory ECG market which would include possible expansion into future alternative markets. Related to this acquisition will be on-going efforts by CBSC to expand My-Cardia's service capabilities leveraging business relationships and exploring additional acquisitions.

**Company Contact Information:** Address:  
340 State Place  
Escondido, CA 92029

Telephone number:  
(888) 225-0870

Emails:  
General inquires: [info@cbscientificinc.com](mailto:info@cbscientificinc.com)  
Investor Inquiries: [investor@cbscientificinc.com](mailto:investor@cbscientificinc.com)

Social Media Outlets: Twitter, Facebook, Instagram, and LinkedIn

CB Scientific plans to make further announcements to keep its shareholders, industry participants and the public markets informed through press releases and regulatory filings, as new developments occur.

*This information disclosure may contain forward-looking statements covered within the meaning of the Private Securities Litigation Act of 1995. These forward-looking statements relate to, among other things, plans and timing for the introduction or enhancement of our services and products, statements about future market conditions, supply and demand conditions, and other expectations, intentions and plans contained in this press release that are not historical fact and involve risks and uncertainties. Our expectations regarding future revenues depend upon our ability to develop and supply products and services that we may not produce today and that meet defined specifications. When used in this press release, the words “plan,” “expect,” “believe,” and similar expressions generally identify forward-looking statements. These statements reflect our current expectations. They are*

*subject to a number of risks and uncertainties, including, but not limited to, changes in technology and changes in pervasive markets. This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.*

#### SIGNATURES

The Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Dated: November 4, 2020**

**CB SCIENTIFIC, INC.**

By: /s/ *Charles Martin*

Charles Martin

President